Radiotherapy is responsible for a significant reduction in breast cancer mortality. However, the treatment may lead to the development of a different cancer or heart disease in the future.
Radiotherapy is responsible for a significant reduction in breast cancer mortality; however, the treatment may lead to the development of a different cancer or heart disease in the future.
A new study, published in the Journal of Clinical Oncology, estimates the risks of radiotherapy for breast cancer through a systematic literature review that includes lung and heart doses in regimens for breast cancer during 2010 to 2015.
The authors conducted a meta-analysis of data from previous randomized trials that compare radiotherapy versus no radiotherapy. The analysis included data on 40,781 women who had participated in 75 clinical trials, and rate ratios for secondary cancer, lung cancer, and cardiac mortality were collected. Patient information, like tumor characteristics, treatments, and cancer recurrence, were considered in the trials.
Following the meta-analysis, the researchers were able to calculate the risks for other cancers among certain population categories with radiotherapy utilization. The risk for lung cancer is approximately 4% for long-term and continuing smokers, and 0.3% for nonsmokers. For cardiac mortality, the absolute risk is estimated at approximately 1% for smokers and 0.3% for nonsmokers.
The study did not discover any information on the association between radiotherapy and heart disease development, and therefore could not draw a conclusion. The researchers also note their limitations in the study, as they did not know all the causes of death or smoking habits among the trial participants. However, the research still demonstrates the influence of radiotherapy on smokers and their risks of future diseases.
“For long-term smokers irradiated today, the estimated combined risks from radiotherapy are a few percentage points if smoking continues, which may outweigh the reduction in breast cancer mortality; however, smoking cessation substantially reduces risk,” concludes the study. “For healthy nonsmokers, the estimated absolute risks of lung cancer or cardiac mortality from radiotherapy add up to < 1%, which, for most women, is much smaller than the benefit from radiotherapy.”
Reference
Taylor C, Correa C, Duane FK, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35(15):1641-1649. doi: 10.1200/JCO.2016.72.0722.
Exploring Possibilities in Disease Modification in MPNs
October 25th 2024Experts are asking whether the study and treatment of myeloproliferative neoplasms (MPNs) is ready for a new era with new end points, with data that show how survival benefits are biologically linked to changes in the spleen, reduction in fibrosis, or other responses.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More